NexImmune to Announce Second Quarter 2021 Financial Results and Provide Corporate Update on August 9, 2021
27. Juli 2021 16:01 ET
|
NexImmune, Inc.
GAITHERSBURG, Md., July 27, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a...
NexImmune Strengthens Management Team with Key Appointments
14. Juli 2021 16:01 ET
|
NexImmune, Inc.
Dr. Jack A. Ragheb as Senior Vice President, Translational ScienceMatt Schiller, Head of Business Development GAITHERSBURG, Md., July 14, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a...
NexImmune to Present at the Raymond James 2021 Human Health Innovation Conference
16. Juni 2021 16:29 ET
|
NexImmune, Inc.
GAITHERSBURG, Md., June 16, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a...
NexImmune Announces Formation of Scientific Advisory Board
27. Mai 2021 08:00 ET
|
NexImmune, Inc.
GAITHERSBURG, Md., May 27, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a...
NexImmune Announces Presentation of Preliminary Phase 1/2 Clinical Data at the 2021 American Society of Clinical Oncology Annual Meeting
19. Mai 2021 16:21 ET
|
NexImmune, Inc.
GAITHERSBURG, Md., May 19, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a...
NexImmune Reports First Quarter 2021 Financial Results and Recent Updates
17. Mai 2021 16:01 ET
|
NexImmune, Inc.
Advancing two lead product candidates in Phase 1/2 clinical trials Completed successful $126M initial public offering (IPO) in February 2021 Additional clinical and preclinical data anticipated in the...
NexImmune Appoints Chad Rubin as Senior Vice President, Corporate Affairs
21. April 2021 07:30 ET
|
NexImmune, Inc.
Mr. Rubin most recently served as Managing Director, Co-Head Life Sciences for Solebury Trout GAITHERSBURG, Md., April 21, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a...
NexImmune Reports Fiscal Year 2020 Financial Results and Recent Updates
31. März 2021 16:54 ET
|
NexImmune, Inc.
In 2020, advanced two product candidates into Phase 1/2 clinical trials while strengthening Board of Directors and management teamCompleted successful $126M initial public offering (IPO) in February...
NexImmune to Present at the 2021 Barclays Global Healthcare Conference
02. März 2021 16:01 ET
|
NexImmune, Inc.
GAITHERSBURG, Md., March 02, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a...
NexImmune Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
17. Februar 2021 18:34 ET
|
NexImmune, Inc.
GAITHERSBURG, Md., Feb. 17, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s...